EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression

Caroline Dotto Amarger, Maria Isabel de Sampaio Rabello, Sofia Chaves Skaf, Fernando Moura, Janaína Pontes Batista Cassoli, Patrícia Taranto, Pedro Luiz Serrano Usón Junior, Rafael Kaliks, Juliana Rodrigues Beal

einstein (São Paulo) · 2025

DOI: 10.31744/einstein_journal/2026rc1689 ↗

Kurz gefasst

Fallbericht in der Zeitschrift einstein (São Paulo), 2025. Verfasst von Caroline Dotto Amarger und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, Brazil. Hauptthemen laut MEDLINE: Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Triple Negative Breast Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is one of the most prevalent and heterogeneous cancers worldwide; however, it remains a complex and enigmatic disease. Advances in targeted therapies combined with increasing knowledge about tumor subtypes and molecular profiling have placed precision medicine on the frontier of oncological treatments. The recent classification of certain HER2 tumors as HER2-low, along with emerging evidence from studies using antibody-drug conjugates to target specific tumor profiles, highlights the relevance of this case study. This report describes the treatment of a 72-year-old woman diagnosed with metastatic triple-negative breast cancer, classified as HER2-low with specific HER2 mutations. The patient showed disease progression despite standard treatments, leading to the use of trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate targeting HER2, as a third-line therapy. Her positive response, which surpassed the median progression-free survival rates seen in clinical trials, highlights the potential of precision medicine, where treatment is customized based on genetic and molecular tumor profiles. These new therapeutic options for difficult-to-treat cancer subtypes expand treatment possibilities, ushering in a new era of personalized and precision-driven oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrastuzumabErb-b2 Receptor Tyrosine KinasesTriple Negative Breast NeoplasmsAntibodies, Monoclonal, HumanizedImmunoconjugatesAntineoplastic Agents, ImmunologicalHumansFemaleAgedMutationTreatment OutcomeCamptothecin

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine Kinasestrastuzumab deruxtecanAntibodies, Monoclonal, HumanizedImmunoconjugatesERBB2 protein, humanAntineoplastic Agents, ImmunologicalCamptothecin

Autor:innen und Institutionen

  • Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Centro de Oncologia e Hematologia Einstein Família Dayan - Daycoval, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
  • Centro de Medicina Personalizada, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.

Zitieren

APA

Amarger, C. D., Rabello, M. I. S., Skaf, S. C., Moura, F., Cassoli, J. P. B., Taranto, P., Serrano Usón Junior, P. L., Kaliks, R., & Beal, J. R. (2025). Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression. einstein (São Paulo). https://doi.org/10.31744/einstein_journal/2026rc1689

Vancouver

Amarger CD, Rabello MIS, Skaf SC, Moura F, Cassoli JPB, Taranto P, et al. Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression. einstein (São Paulo). 2025. doi:10.31744/einstein_journal/2026rc1689

BibTeX
@article{Amarger2025,
  author = {Amarger, Caroline Dotto and Rabello, Maria Isabel de Sampaio and Skaf, Sofia Chaves and Moura, Fernando and Cassoli, Janaína Pontes Batista and Taranto, Patrícia and Serrano Usón Junior, Pedro Luiz and Kaliks, Rafael and Beal, Juliana Rodrigues},
  title = {Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression},
  journal = {einstein (São Paulo)},
  year = {2025},
  doi = {10.31744/einstein_journal/2026rc1689}
}
Kostenlos starten →